Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus

Figure 1 In non-diabetic patients, L-arginine by far outweighs asymmetric dimethylarginine, and active nitrogen oxide modulates vascular tone and structure. DDAH: Dimethylarginine dimethylaminohydrolase; ADMA: Asymmetric dimethylarginine; LDL: Low-density lipoprotein; NO: Nitrogen oxides.

Figure 2 Protocols of our clinical research.

Figure 3 The result of diabetic cardiovascular disease that developed within five years. The numbers without parentheses mean new developments, and the numbers with parentheses mean recurrences.

Figure 4 Asymmetric dimethylarginine was significantly higher in diabetic cardiovascular disease development group than in diabetic cardiovascular disease non-development group.